Sirona Biochem (Seite 3104)
eröffnet am 23.06.13 12:55:10 von
neuester Beitrag 08.05.24 17:10:08 von
neuester Beitrag 08.05.24 17:10:08 von
Beiträge: 31.047
ID: 1.183.167
ID: 1.183.167
Aufrufe heute: 113
Gesamt: 5.405.460
Gesamt: 5.405.460
Aktive User: 0
ISIN: CA82967M1005 · WKN: A0RM6R
0,0440
EUR
+1,15 %
+0,0005 EUR
Letzter Kurs 22:26:31 Tradegate
Neuigkeiten
07.05.24 · IRW Press |
07.05.24 · globenewswire  |
08.04.24 · globenewswire |
05.04.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 7,9900 | +59,80 | |
| 1,6905 | +50,94 | |
| 3,0700 | +31,76 | |
| 1,1800 | +31,11 | |
| 0,8458 | +29,13 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6860 | -12,82 | |
| 2,4550 | -13,25 | |
| 1,6160 | -16,53 | |
| 19,740 | -18,06 | |
| 0,5750 | -18,44 |
Beitrag zu dieser Diskussion schreiben
Feedback!
Dieser Beitrag wurde von a.mueller moderiert. Grund: Spam, Werbung
völlig substanzlos die posting von den kritikern bis jetzt. na ja. DYOR. Q3 wird wird zeigen was in bei Sirona Biochem steckt oder nicht
Zitat von Jon_Schnee: SGLT2 Inhibitors A New Class of Diabetes Drugs
SGLT2 inhibitor’s NOVEL mechanism of action blocks re-uptake of glucose from the kidney and may also improve obesity profile.
Markt:
More than 371 million people have diabetes.
By 2030, this will rise to 552 million.
Last year, 4.6 million people died due to diabetes or related complications and more than $471 billion US were spent on healthcare for diabetes.
Global prevalence is drastically increasing.
Na klar, den 371 000 000 Kranken wird ab sofort wirksam geholfen werden..
und so Geld gescheffelt werden.
So einfach ist das an der Börse.
Hier sind einige schnell mit Ihrem Urteil 
. Ich traue Sirona Biochem im positiven Sinne sehr viel zu. Der Schlüssel ist die Plattform/Technik:
http://www.sironabiochem.com/products/proprietary-platform/
http://www.youtube.com/watch?feature=player_embedded&v=F_fAz…
Sirona Biochem has expertise in the development of carbohydrate-based molecules. Essential to life, carbohydrates, or sugar molecules, have broad potential for ground-breaking pharmaceutical and cosmetic development. Despite this immense potential, a major limitation of carbohydrate molecules is their lack of stability. When coming into contact with omnipresent enzymes, for example, carbohydrate-based molecules can easily break down or become toxic, making them difficult to produce as pharmaceutical products.
Sirona Biochem’s French subsidiary, TFChem, has developed a proprietary chemistry technique that maintains the integrity of carbohydrate-based molecules even after enzyme exposure. Through years of award-winning research by our synthetic chemists, we have learned how to strengthen the bond of a carbohydrate molecule by strategically placing fluorine atoms within the molecule. This technique has yielded several compounds showing promise for the development of different kinds of therapeutics, cosmetic agents and as biological ingredients for laboratory use.
Our research so far has demonstrated that by applying our chemistry technique we can enhance the stability and bioavailability of carbohydrate-based molecules. Our proprietary fluorine-based chemistry platform not only gives our company the chance to develop new robust compounds, but also allows us to improve previously-developed compounds by other companies. Those compounds may have been put on hold because of the inherent challenges of carbohydrate-based chemistry.
. Ich traue Sirona Biochem im positiven Sinne sehr viel zu. Der Schlüssel ist die Plattform/Technik:http://www.sironabiochem.com/products/proprietary-platform/
http://www.youtube.com/watch?feature=player_embedded&v=F_fAz…
Sirona Biochem has expertise in the development of carbohydrate-based molecules. Essential to life, carbohydrates, or sugar molecules, have broad potential for ground-breaking pharmaceutical and cosmetic development. Despite this immense potential, a major limitation of carbohydrate molecules is their lack of stability. When coming into contact with omnipresent enzymes, for example, carbohydrate-based molecules can easily break down or become toxic, making them difficult to produce as pharmaceutical products.
Sirona Biochem’s French subsidiary, TFChem, has developed a proprietary chemistry technique that maintains the integrity of carbohydrate-based molecules even after enzyme exposure. Through years of award-winning research by our synthetic chemists, we have learned how to strengthen the bond of a carbohydrate molecule by strategically placing fluorine atoms within the molecule. This technique has yielded several compounds showing promise for the development of different kinds of therapeutics, cosmetic agents and as biological ingredients for laboratory use.
Our research so far has demonstrated that by applying our chemistry technique we can enhance the stability and bioavailability of carbohydrate-based molecules. Our proprietary fluorine-based chemistry platform not only gives our company the chance to develop new robust compounds, but also allows us to improve previously-developed compounds by other companies. Those compounds may have been put on hold because of the inherent challenges of carbohydrate-based chemistry.
Trading Spotlight
Antwort auf Beitrag Nr.: 44.903.911 von Jon_Schnee am 23.06.13 12:55:10Neben Diabetes SGLT Inhibitor & Skin lightener (wie schon erwähnt erwarte ich hier bald ePartnerschaften mit sehr grossen Unternehmen) wurden folgende Vereinbarungen getroffen (weiter werden folgen):
Sirona Biochem Announces LOI for Collaboration with Cincinnati Children’s Hospital Medical Center
http://www.sironabiochem.com/sirona-biochem-announces-loi-fo…
Sirona Biochem Signs Material Transfer Agreement with VitamFero
http://www.sironabiochem.com/sirona-biochem-signs-material-t…
Sirona Biochem Announces LOI for Collaboration with Cincinnati Children’s Hospital Medical Center
http://www.sironabiochem.com/sirona-biochem-announces-loi-fo…
Sirona Biochem Signs Material Transfer Agreement with VitamFero
http://www.sironabiochem.com/sirona-biochem-signs-material-t…
Antwort auf Beitrag Nr.: 44.904.087 von sukraman am 23.06.13 13:49:37Gibt es Namenskonflikte mit Sirona Dental?
Zumindest Juristisch nicht - aber Verwechslungsgefahr durch aus möglich.
Zumindest Juristisch nicht - aber Verwechslungsgefahr durch aus möglich.
Antwort auf Beitrag Nr.: 44.903.991 von Datteljongleur am 23.06.13 13:21:38Ich möchte mal wissen, wie risikobereit (oder verzweifelt?!) man eigentlich sein muss, um solche Aktien zu kaufen!
Ich meine, die Dinger kann man ja eigentlich nicht mal mehr als Penny-Stock begreifen.
Ich meine, die Dinger kann man ja eigentlich nicht mal mehr als Penny-Stock begreifen.
Antwort auf Beitrag Nr.: 44.904.033 von Jon_Schnee am 23.06.13 13:32:35Gibt es Namenskonflikte mit Sirona Dental?
Antwort auf Beitrag Nr.: 44.903.911 von Jon_Schnee am 23.06.13 12:55:10Video: Marcum Conference 2013
http://www.equities.com/media-gallery/173-sirona-biochem-cor…
Neil Belenkie of Sirona Biochem Corp. (SBM) chats about their company's development of drug compounds for the treatments of type 2 diabetes and obesity with Equities.com
http://www.equities.com/media-gallery/173-sirona-biochem-cor…
Neil Belenkie of Sirona Biochem Corp. (SBM) chats about their company's development of drug compounds for the treatments of type 2 diabetes and obesity with Equities.com
Durchsuchen
Sirona Biochem
